Information  X 
Enter a valid email address

Nanoco Group PLC (NANO)

  Print          Annual reports

Wednesday 24 March, 2021

Nanoco Group PLC

Amendment to Executive Director Service Terms

RNS Number : 3893T
Nanoco Group PLC
24 March 2021
 

24 March 2021

NANOCO GROUP PLC

(" Nanoco ", the "Group" or the "Company" )

 

AMENDMENT TO EXECUTIVE DIRECTOR SERVICE TERMS

Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other specific nanomaterials emanating from our technology platform, has today rescinded the notice served on Dr Nigel Pickett (CTO) that his employment would come to an end on 29 March 2021, as communicated in the RNS dated 30 March 2020.

The Company has now agreed a new employment contract with Dr Pickett, which comes into effect immediately.  The contract is materially the same as the previous agreement, except that the contractual notice period has been reduced from 12 months to 6 months.

Dr Christopher Richards, Nanoco's Chairman, commented:

"Nigel is a critical member of the Executive team and of the Board.  His leadership of Nanoco's technology R&D is critical to our ongoing development activities, as well as to our litigation with Samsung.  We appreciate Nigel's support and patience during the recent months of uncertainty."

For further information, please contact:

Nanoco Group PLC :

Brian Tenner, CEO  +44 (0) 161 603 7900

Liam Gray, Company Secretary +44 (0) 161 603 7900

Caroline Watson, Investor Relations Manager                                                        +44 (0) 161 603 7900

[email protected]

 

MHP Communications :                                                                                       +44 (0) 203 128 8570

Reg Hoare

Giles Robinson

Pete Lambie

[email protected]

 

= END =

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCUSOVRASUOUAR

a d v e r t i s e m e n t